Altimmune, Inc. (ALT)
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.
ALT Pemvidutide Explained: What Makes It Different in MASH
Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.
Altimmune: The High Cost Of Going Solo (Rating Downgrade)
Altimmune, Inc. appears undervalued on risk-adjusted NPV but faces severe funding and competitive headwinds. Pemvidutide's Phase 3 MASH program is ambitious, requiring significant capital, and now includes titration, impacting its tolerability edge. The pipeline's AUD and ALD indications have negative risk-adjusted NPVs and further strain ALT's financial position.
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly
Shares of Altimmune ( NASDAQ:ALT ) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit.
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
Altimmune delivered strong 48-week Phase IIb data for pemvidutide in MASH, supporting progression to Phase III. Pemvidutide showed durable, dose-dependent improvements in non-invasive fibrosis markers and consistent safety, with weight loss reaching 7.5% at 1.8 mg. Regulatory alignment for a Phase III trial targeting accelerated approval appears promising, with biopsy-based endpoints and a planned 2.4 mg dose.
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?
The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
